CClinicalTrials.gg
Not yet recruitingNCT07265687Updated Dec 5, 2025

Impact of Magnetic Stimulation on Pain in Endometriosis Patients

An interventional study of Magnetic stimulation in Endometriosis, sponsored by Kantonsspital Winterthur KSW. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Kantonsspital Winterthur KSW · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Many women with endometriosis still experience pain despite surgical and medical treatment. Over-the-counter painkillers are usually helpful in alleviating this pain. But for some patients, these medications eventually stop working. Pain then dominates their daily life. In this study, we are investigating the effects of magnetic stimulation using the "Tesla chair" and whether it can alleviate their pain

Read the detailed description

Patients who are diagnosed with CPP and hypertonic pelvic floor as assessed in gynaecological exam will be asked to participate. Before start of the Tesla chair treatment VAS Score by PPAF will be assessed. After 6 treatments (after 3 weeks an intermediate doctor's consultation will rule out aggravation of CPP by treatment and if possible the next cycle of 6 treatments will be scheduled. After completion of 12 treatments the VAS Score will be reassessed and treatments' success evaluated in a doctor's consultation. We plan to re-evaluate sustaining success after 3 months after treatments completion

02

Conditions studied

  • Endometriosis

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patient has been informed about study
  • Age ≥ 18 years
  • Premenopausal
  • histologically or laparoscopically or MRI confirmed endometriosis
  • CPP (cyclical pelvic pain VAS ≥ 5)
  • Pelvic floor hypertonicity
  • Written informed consent
  • sufficient German speaking
  • Current endocrine therapy for >= 3 months

Exclusion criteria

Exclusion Criteria:

  • Contraindications according manufactureres manual Tesla Chair
  • Pregnancy or desire to become pregnant within the next 8 weeks
  • Pelvic organ prolapses
  • Genital infections
  • Menstruation
  • active malignancy, Malignant tumors
  • Severe neurological diseases
  • Cardiac arrhythmia
  • Active internal medical devices e.g. cardiac pacemakers, medication, pumps etc.
  • Ferromagnetic implants at or near the site of stimulation
  • Recent surgery at the site of stimulation
  • Thrombosis or thrombophlebitis
  • Epilepsy or suspected epilepsy
  • Acute stages of kidney stones
  • Gastrointestinal and internal disease at the site of stimulation
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
  • Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation
  • Previous enrolment into the current investigation
  • Enrolment of the Sponsor or PI, their family members, employees and other dependent persons
  • No endocrine therapy or use of endocrine therapy for \< 3 months
  • active inflammatory diseases
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Tesla-Chair

    Device: Magnetic stimulation

Interventions

  • DeviceMagnetic stimulation

    Magnetic stimulation using the Tesla-Chair

05

What researchers measure

Primary outcomes

  1. Decrease of PPAF-Score before and after treatment.

    Relief of pain measured by changes in PPAF (Pelvic pain assessment form) score before and after the treatment. 0= no pain, 10 = unbearable pain

    Time frame: From enrollment to the end of tratment at end of week 7

Secondary outcomes

  1. Decrease of PPAF-Score before and after treatment.

    Relief of pain measured by changes in PPAF (Pelvic pain assessment form) score before and after the treatment. 0= no pain, 10 = unbearable pain

    Time frame: From enrollment to 3 months after completion of treatment

Other outcomes

  1. Subjective experience of patients, decrease in analgetic use

    Subjective experience of patients, decrease in analgetic use, subjective success

    Time frame: From enrollment to 3 months after completion of treatment

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07265687
Lead sponsor
Kantonsspital Winterthur KSW
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Jan 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Dec 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion